{"id":206142,"date":"2026-06-17T07:14:23","date_gmt":"2026-06-17T07:14:23","guid":{"rendered":"https:\/\/www.europesays.com\/ee\/206142\/"},"modified":"2026-06-17T07:14:23","modified_gmt":"2026-06-17T07:14:23","slug":"ravimite-kallid-hinnad-%e2%9f%a9-karmen-joller-tuleb-teha-raskeid-valikuid-kelle-ravi-saab-rahastada-kohe","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ee\/206142\/","title":{"rendered":"RAVIMITE KALLID HINNAD \u27e9 Karmen Joller: tuleb teha raskeid valikuid, kelle ravi saab rahastada kohe"},"content":{"rendered":"<p>Kohtumise keskne teema oli Euroopa tervisebiotehnoloogia pakett, mille eesm\u00e4rk on toetada uudsete biotehnoloogiliste ravimite, ravimeetodite ja tervisetehnoloogiate arendamist ning kasutuselev\u00f5ttu Euroopas. Uued biotehnoloogilised lahendused v\u00f5ivad t\u00e4hendada paremat v\u00e4hiravi, t\u00e4psemaid uuringuid, kiiremini diagnoosi panemist v\u00f5i uusi v\u00f5imalusi ravida haiguseid, mille puhul praegu head ravi veel ei ole.<\/p>\n<p>Karmen Jolleri s\u00f5nul on bioloogilised ravimid meditsiinis \u00fcks viimaste aastak\u00fcmnete suurimaid l\u00e4bimurdeid ning nende m\u00f5ju on v\u00f5rreldav antibiootikumide ja vaktsiinide omaga. Ta r\u00f5hutas, et innovatsiooni toetamine peab olema tasakaalus ravimite k\u00e4ttesaadavusega. Euroopa Liidus ei tohiks kehtestada reegleid, mis p\u00f5hjendamatult l\u00fckkavad edasi uute ja originaalist soodsamate bioloogiliselt sarnaste ravimite ehk biosimilaride turule j\u00f5udmist. Biosimilarid on sageli ligikaudu kolmandiku v\u00f5rra odavamad kui originaalravimid.<\/p>\n<p><img decoding=\"async\" class=\"figure__image\" onclick=\"triggerEvent('articleImageClick', { id: 17687055, focus: 'single-image', focusIndex: '17687055' })\" onkeydown=\"if (event.key === 'Enter') {&#10;        triggerEvent('articleImageClick', { id: 17687055, focus: 'single-image', focusIndex: '17687055' })&#10;        }\" role=\"button\" tabindex=\"0\" data-focus-from=\"single-image\" data-focus-index=\"17687055\" src=\"https:\/\/www.europesays.com\/ee\/wp-content\/uploads\/2026\/06\/1781618772_531_17687055t1h2c78.jpg\"  onload=\"this.parentElement.classList.remove('figure__image-loading')\" alt=\"Eesti Vabariigi sotsiaalminister Karmen Joller\"\/>Eesti Vabariigi sotsiaalminister Karmen Joller Foto: Elmo Riig<\/p>\n<p>\u00abKui \u00fche ravimi hind on aastaid v\u00e4ga kallis ja konkurentsi tekkimine on takistatud, tuleb teha raskeid valikuid \u2013 kelle ravi saab rahastada kohe ja kelle ravi peab ootama. Meie eesm\u00e4rk on, et uued ravimid j\u00f5uaksid inimesteni kiiremini,\u00bb \u00fctles Joller. \u00abKui ravimiturul tekib aus konkurents, v\u00f5idavad patsiendid. Hind langeb, k\u00e4ttesaadavus paraneb ja tervishoius\u00fcsteem saab sama raha eest rohkem abi pakkuda.\u00bb<\/p>\n<p>Eesti vaatest v\u00f5ib uutele ravimitele anda pikema kaitseperioodi vaid siis, kui selleks on kindel p\u00f5hjus. N\u00e4iteks juhul, kui ravim aitab haiguse korral, millele seni head ravi ei ole, v\u00f5i annab patsiendile olemasolevate ravimitega v\u00f5rreldes parema tulemuse. Kui lisakaitset antakse liiga lihtsalt ja konkurents on takistatud, l\u00fckkub odavamate ravimite turule j\u00f5udmine edasi.<\/p>\n","protected":false},"excerpt":{"rendered":"Kohtumise keskne teema oli Euroopa tervisebiotehnoloogia pakett, mille eesm\u00e4rk on toetada uudsete biotehnoloogiliste ravimite, ravimeetodite ja tervisetehnoloogiate arendamist&hellip;\n","protected":false},"author":2,"featured_media":205473,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[12],"tags":[84350,84355,26,27,37,33,35,84352,21395,84357,34,36,590,84354,31,32,21,1793,84351,28,29,19,50278,25,84356,80354,28739,84353,21521,23,24,22,20,30],"class_list":["post-206142","post","type-post","status-publish","format-standard","has-post-thumbnail","category-eesti","tag-bioloogiline-ravim","tag-biosimilar","tag-breaking-news","tag-breakingnews","tag-ee","tag-eesti","tag-eesti-keel","tag-eesti-sotsiaalminister","tag-elundisiirdamine","tag-elundite-sailitamistehnoloogia","tag-estonia","tag-estonian","tag-euroopa-liit","tag-euroopa-tervisebiotehnoloogia-pakett","tag-featured-news","tag-featurednews","tag-headlines","tag-karmen-joller","tag-konkurentsipoliitika","tag-latest-news","tag-latestnews","tag-news","tag-patsiendiohutus","tag-populaarseimad-lood","tag-ravimihind","tag-ravimite-kattesaadavus","tag-ravimiturg","tag-terviseministrite-kohtumine","tag-tervishoiususteem","tag-top-stories","tag-topstories","tag-uldised-uudised","tag-uudised","tag-viimased-uudised"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/206142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/comments?post=206142"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/206142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media\/205473"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media?parent=206142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/categories?post=206142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/tags?post=206142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}